For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for IDEXX Laboratories, Inc. (IDXX) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score +3 (−100…+100 Quality+Value blend) · Quality 87 · Value -65 · Sentiment 33 (timing only, not weighted) · Composite fair value $220.75 vs $575.26 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
IDEXX Laboratories, Inc.
IDXX NASDAQIDEXX Laboratories, Inc. is a healthcare diagnostics company specializing in products and services for the veterinary, livestock, poultry, dairy, and water testing markets. The company develops and manufactures diagnostic test kits, in-clinic analyzers, and reference laboratory services that support veterinarians in diagnosing and monitoring health conditions in companion animals. IDEXX Laboratories, Inc. also provides management software, digital imaging systems, and data analytics tools that help veterinary practices streamline workflows and clinical decision-making. Beyond companion animals, the company offers testing solutions for livestock and poultry health, dairy quality, and water microbiology, supporting food safety and public health monitoring. Its operations are organized into segments including Companion Animal Group, Water, Livestock, Poultry, and Dairy, and other related services. Founded in 1983 and headquartered in Westbrook, Maine, IDEXX Laboratories, Inc. plays a significant role in modern animal health diagnostics and environmental testing worldwide.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 13.08
Total Equity: $1.61B
Shares: 81,025,000
Total Debt: $449.84M
Cash: $180.07M
EBITDA: $1.51B
Total Debt: $449.84M
Cash: $180.07M
Revenue: $4.30B
Revenue: $4.30B
Revenue: $4.30B
Total Equity: $1.61B
Tax Rate: 20.0%
Equity: $1.61B
Total Debt: $449.84M
Cash: $180.07M
Current Liabilities: $1.15B
Long-Term Debt: $374.84M
Total Debt: $449.84M
Total Equity: $1.61B
Shares: 81,025,000
Shares: 81,025,000
CapEx: -$124.68M
Shares: 81,025,000
Stock Price: $562.88
Net Income: $1.06B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 3, 2026 1:19pm (20d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.2B | $3.4B | $3.7B | $3.9B | $4.3B |
| Cost of Revenue | $1.3B | $1.4B | $1.5B | $1.5B | $1.6B |
| Gross Profit | $1.9B | $2.0B | $2.2B | $2.4B | $2.7B |
| Operating Expenses | $957.4M | $1.1B | $1.1B | $1.3B | $1.3B |
| Operating Income | $932.0M | $898.8M | $1.1B | $1.1B | $1.4B |
| Net Income | $744.8M | $679.1M | $845.0M | $887.9M | $1.1B |
| EBITDA | $1.0B | $1.0B | $1.2B | $1.3B | $1.5B |
| EPS | $8.74 | $8.12 | $10.17 | $10.77 | $13.17 |
| EPS (Diluted) | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 |
Balance Sheet (Annual)
Last updated: Aug 3, 2026 12:50pm (20d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $144.5M | $112.5M | $453.9M | $288.3M | $180.1M |
| Total Current Assets | $955.7M | $1.1B | $1.5B | $1.4B | $1.4B |
| Total Assets | $2.4B | $2.7B | $3.3B | $3.3B | $3.4B |
| Current Liabilities | $763.6M | $1.2B | $951.5M | $1.1B | $1.1B |
| Long-Term Debt | $775.2M | $694.4M | $622.9M | $449.8M | $374.8M |
| Total Liabilities | $1.7B | $2.1B | $1.8B | $1.7B | $1.7B |
| Total Equity | $690.0M | $608.7M | $1.5B | $1.6B | $1.6B |
| Retained Earnings | $2.9B | $3.6B | $4.4B | $5.3B | $6.4B |
Cash Flow (Annual)
Last updated: Aug 3, 2026 1:19pm (20d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $755.5M | $543.0M | $906.5M | $929.0M | $1.2B |
| Capital Expenditure | -$119.5M | -$148.8M | -$133.6M | -$120.9M | -$124.7M |
| Free Cash Flow | $636.0M | $394.1M | $772.9M | $808.1M | $1.1B |
| Acquisitions (net) | -$173.4M | -$11.5M | $0 | -$76.7M | $0 |
| Net Debt Issued / (Repaid) | $0 | $0 | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$746.8M | -$819.7M | -$71.9M | -$837.0M | -$1.2B |
| Net Change in Cash | -$239.5M | -$31.9M | $341.4M | -$165.7M | -$108.2M |
Growth Trends (YoY %)
Last updated: Aug 3, 2026 1:19pm (20d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +4.7% | +8.7% | +6.5% | +10.4% |
| Gross Profit Growth | +6.1% | +9.3% | +8.6% | +11.8% |
| Operating Income Growth | -3.6% | +22.1% | +2.8% | +20.5% |
| Net Income Growth | -8.8% | +24.4% | +5.1% | +19.3% |
| EBITDA Growth | -2.5% | +19.9% | +3.8% | +19.6% |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 09:00Even the bull case prices 72% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 78%.
| Case | Growth | Margin | Fair value | vs price ($575.26) |
|---|---|---|---|---|
| Bull — recovery | +16% | 28.8% | $162.63 | -72% |
| Base — stabilizes | +10% | 25.0% | $123.56 | -79% |
| Bear — keeps slipping | +5% | 21.3% | $92.27 | -84% |
| Stress — last quarter repeats | +10% | 26.0% | $124.73 | -78% |
Narrative Economics
market-narrative step).
Claude Reading
IDXX prints roughly $4.3B revenue TTM (extrapolating Q1'26 at $1.14B, up 14% YoY from Q1'25's $998M — actually an *acceleration*, not deceleration), operating margin holding 31.6%, ROIC of 58%, and FCF of $1.06B on $44B market cap. That's a 2.4% FCF yield. The business is unimpeachable: 62% gross margin, veterinary consumables razor-blade lock-in, $450M debt against $1.2B operating cash flow — this is exactly the kind of asset that trades expensive because it deserves to. The quarterly cadence is Q1'25 $998M → Q2 $1.11B → Q3 $1.11B → Q4 $1.09B → Q1'26 $1.14B; ex-seasonality that's a genuine reacceleration from the 2024 slog when quarters printed $975-1,000M with visible pandemic-boom digestion. Earnings YoY of 19.3% on 10.4% revenue growth confirms operating leverage is live.
The synthesis's $224 fair value implies a ~60% haircut and rests on 6-8% perpetual growth with normalized margins. I think that's too punitive. IDXX has compounded revenue at 8.4% CAGR *through* a post-COVID pet-visit normalization — the hard part is arguably behind. If you underwrite 9-10% revenue growth for five years with 100-150bps of margin expansion (software/CAG Dx premium mix), you get to something like $1.55B FCF by 2030; slap a 30x multiple (defensible for this quality) and discount back at 9%, you're closer to $400-430, not $224. The DCF model appears to be assuming multiple compression AND growth deceleration simultaneously, which is a bearish double-count. That said, $562 still needs ~11-12% growth or terminal multiple heroics to clear a 10% IRR hurdle. The narrative layer's "$350 of premium" call is directionally right even if the anchor is too low.
Where the models diverge and I side with skepticism of the synthesis: Market Forces calls "tailwinds" while Synthesis calls "overvalued" — both can be true, but the Narrative layer's framing (anchored, platform-monopoly, moderate durability) is the most honest read. The contrarian argument the models underweight: veterinary visit volumes in the US have been *flat-to-down* per Vetsource/AAHA data through 2024-2025 even as IDXX grew via pricing and mix — that's a pricing engine, not a volume engine, and pricing power in a discretionary-adjacent category has a ceiling when pet owners face inflation fatigue. Also worth flagging: the insider table shows only awards and option exercises with in-kind tax withholding — zero open-market buying at $560+. Management with 58% ROIC and "irreplaceable moat" conviction isn't putting personal capital to work here. That's a quiet tell.
Data quality flags: the "2026-03-31" quarter tag is suspicious — either this is a mislabeled fiscal period or the file is time-shifted; I'm treating it as the most recent reported quarter regardless, but a reviewer should verify. The 24.4% net margin in that quarter is a step-up from Q4's 22.8%, worth confirming isn't a one-time tax item. The pre-flight's "down from 52-week high" claim isn't supportable from the data provided. Finally, macro headwinds + decelerating quarterly trend flags in Secondary Signals contradict my read of the sequential data — I think the "deceleration" tag is stale or based on the Q4 dip that Q1 already reversed.
GPT Reading
IDEXX looks like exactly the kind of business that deserves a premium, but not this premium. The operating profile is exceptional: 2025 revenue was $4.30B, up 10.2% from $3.90B in 2024, while operating income rose to $1.36B from $1.13B and net income to $1.06B from $887.9M. That is real scaling, not financial engineering. Gross margin at 61.8%, operating margin at 31.6%, and net margin at 24.6% are elite for a diagnostics franchise, and free cash flow of $1.06B on $1.06B of net income shows the earnings quality is clean. The balance sheet is also not the issue: $449.8M of debt against $180.1M of cash and $1.18B of operating cash flow is conservative enough. If I were judging only the business, I would call it one of the best compounders in healthcare.
The quarterly trend is also better than the “mature earner” label implies. Revenue moved from $998.4M in 1Q25 to $1.14B in 1Q26, and net income from $242.7M to $278.4M, for 10.4% top-line growth and 14.7% bottom-line growth year over year in the latest quarter. Over the last eight quarters, revenue has climbed from roughly $954M-$1.00B run-rate in 2024 to consistently $1.09B-$1.14B in the most recent four quarters. Margins have held in a narrow and impressive band, mostly 23%-26%, aside from one softer 20.3% quarter in mid-2024. That tells me the moat is real: recurring consumables, installed systems, and pricing discipline are offsetting whatever macro wobble exists in vet visit volumes. The model outputs that slap a low-$200s fair value on this business look too harsh on quality and too dismissive of durability.
But even giving IDEXX full credit for quality, today’s valuation still asks too much. At $562.88, the stock trades at 43x earnings, 10.6x sales, and about 30x EV/EBITDA. On trailing net income of $1.06B, the earnings yield is only about 2.4%; on free cash flow of $1.06B, the FCF yield is also roughly 2.4% on a $44.1B market cap. Those are not impossible multiples for a business growing 20%-plus, but IDEXX is not doing that on revenue; the annual revenue CAGR is 8.4%, and even the latest quarterly growth is just above 10%. To underwrite this price, I think you need confidence that IDEXX can sustain double-digit revenue growth while also continuing margin expansion from already-high levels. That is a demanding setup for a company already earning 31.6% operating margins in a niche end market. A wonderful business can still be a poor stock if the entry price bakes in too much perfection, and that is where I land here.
The smartest bull rebuttal is that “too expensive” has been the wrong call on this name for years because the franchise compounds, the switching costs are high, and incremental revenue is unusually profitable. They would point to ROIC of 58.0%, ROE of 66.0%, and the fact that 2021 to 2025 revenue rose from $3.22B to $4.30B while net income climbed from $744.8M to $1.06B. They would also argue that the quarterly data shows re-acceleration rather than decay: 1Q26 revenue of $1.14B was not only up 10.4% year over year but above every prior quarter in the data set, and the margin stayed at 24.4%. That case has substance, and it is why I do not agree with the extreme bearishness implied by a $220 fair value. Still, I weigh the multiple more heavily because this is no longer a hidden compounder; it is priced as a near-flawless one. When a company on 10.6x sales is growing 8%-10%, even small disappointments in volume, pricing, or mix can compress the multiple far faster than earnings grow.
What would change my mind is straightforward. I would get more constructive if IDEXX can print several more quarters of 11%-13% revenue growth while keeping net margins at or above 24%, pushing annualized earnings power toward $1.2B-$1.3B without leverage or one-offs; that would better justify a premium multiple and support the idea that the TAM is still opening. I would also change my view if the stock corrected into the low-to-mid $400s, where the FCF yield and earnings multiple would better match a high-quality 8%-12% grower. Conversely, if revenue slips back to mid-single digits or margins stall around current levels, the market’s willingness to pay 43x earnings should break quickly.
Grok Reading
IDEXX’s financial engine is unmistakably elite. Annual revenue climbed from $3.22B in 2021 to $4.30B in 2025, a clean 8.4% CAGR that has recently re-accelerated to 10.4% year-over-year, with the March 2026 quarter printing $1.14B. Earnings have compounded faster at 12%, and free-cash-flow CAGR of 17% has outrun both, delivering $1.06B of FCF in 2025 on only $125M of capex—near-perfect conversion. Gross margin sits at 61.8%, operating margin has expanded to 31.6%, and net margin holds 24.6%. Returns are exceptional: ROIC 58%, ROE 66%, ROA 32%. Leverage is trivial at $450M debt against $1.61B equity and a 0.28 D/E, so the balance sheet is not the constraint. The story the numbers tell is a high-ROIC, capital-light diagnostics franchise still taking share inside a structurally sticky installed base of analyzers and consumables.
That quality, however, is already more than fully reflected—and then some—at $562.88. Trailing P/E of 43×, EV/EBITDA of 30× and 10.6× sales leave a free-cash-flow yield of roughly 2.4%. Even granting the recent 19% earnings growth spike, a PEG near 3.5× is aggressive for a business whose long-term revenue trajectory is mid-to-high single digits in a finite veterinary TAM. The valuation synthesis placing fair value near $224 is too punitive (it under-weights the durability of the moat and the 60%+ gross margin), yet the direction is correct: the stock embeds perpetual low-teens growth plus further multiple expansion that the underlying 8–10% organic run-rate and post-pandemic normalization of pet visits do not support. Narrative is carrying several hundred dollars of the price; the fundamentals alone do not.
The strongest counter-argument is straightforward and data-backed. ROIC above 50% with expanding operating margins and a recurring-revenue lock-in is rare; peers in diagnostics rarely clear 20% ROIC. Recent quarters show no crack—revenue held above $1.09B for four straight periods, net income margins stayed 23–26%, and FCF quality is pristine. A quality compounder that can sustain 12% earnings growth and inch operating margins higher via software mix can justify 32–35× forward earnings; on 2026E net income near $1.2B that still implies $480–530, not collapse to $224. Recession-resistant vet spend and pricing power have historically protected the multiple through cycles, so calling the entire premium a bubble overstates the risk of mean-reversion.
I would reverse to a neutral or constructive stance if the next two quarters deliver sustained organic revenue growth above 12% with operating margin expansion past 33%, or if management credibly expands the addressable market via new modalities that push the multi-year revenue CAGR back into the low teens. Conversely, any print of mid-single-digit revenue growth or sequential margin compression would confirm the multiple is simply too high and push fair value closer to the mid-$300s.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
IDXX is a textbook mature compounder. Revenue climbed from 3.22B in 2021 to 4.30B in 2025 (roughly 7.5% CAGR), gross margin expanded 300bps from 58.8% to 61.8%, operating margin ratcheted to 31.6%, and net income grew from 744.8M to 1.06B. Free cash flow tracks earnings almost exactly (FCF 1.06B vs NI 1.06B; OCF/NI 1.01x), and accruals are actually negative (-0.5% of assets), meaning reported profits are backed by cash rather than paper. Capital discipline reinforces the operating quality: diluted share count fell from 86.6M to 81.0M (roughly -1.6% CAGR), SBC is a modest 1.4% of revenue, and buybacks run 13.8x SBC, so per-share value is being concentrated. Beneish M of -2.5 and an Altman Z of 20.55 leave no mechanical red flags. Insider tape is routine equity comp and tax-withholding, with no open-market buys or sells to signal anything either way. The one honest caveat is balance-sheet posture: 180M of cash against net debt of 269.8M means the cushion is the cash flow engine itself, not the balance sheet. Given 1.06B of annual FCF that is a trivial constraint, but it does mean the company is not a literal fortress in the cash-hoard sense; it is a fortress in the earnings-quality and franchise-durability sense.
Verify before trusting this (5)
- Debt maturity schedule and interest coverage detail behind the 269.8M net debt figure
- Segment mix and organic vs acquired growth split within the 4.30B revenue base
- Customer/geographic concentration in the CAG Diagnostics recurring revenue stream
- Whether the margin expansion reflects pricing power or mix shift toward higher-margin instruments/consumables
- Any pending litigation or regulatory exposure not visible in the mechanical modules
The e2e composite fair value of $201 (signal-adjusted $224) implies -60% downside, but that math is heavily dragged by an EPV floor of $92 and a DCF of $132 that clearly under-weight IDEXX's durable mid-teens compounding and recurring razor-blade economics. The anchored-PE of $448 is the more credible reference point for a Fortress-grade franchise, and even that sits ~22% below the $575 print. Triangulating a defensible deserved value in the $425-500 range against today's price, the gap is a rich premium of roughly 15-30%, not the 60% collapse the composite suggests.
Verify before trusting this (5)
- CAG Diagnostics recurring revenue organic growth trend in the next print
- US clinical visit trends — is the post-pandemic normalization stabilizing or still declining
- Pricing vs volume mix in guidance
- Any share-count / buyback pace change
- Competitive commentary on Zoetis / Antech encroachment
The dominant force on IDXX is narrative, not tape: a strong platform-monopoly story with moderate durability and medium cult following is doing the heavy lifting, framing the name as an irreplaceable vet-diagnostics compounder. That story has propelled price well past what a normalized DCF supports, which is itself evidence the narrative is winning the sentiment battle right now. Momentum is positive and improving leverage plus cash generation give bulls talking points that keep the story intact. The macro tape is mildly constructive (neutral-to-tailwind, VIX 16, S&P near highs), but IDXX carries a 1.55 beta, so any risk-off shift would hit harder than average - for now, calm tape lets the story run. Rates at 4.68% and a 26.9 market PE are a background headwind for a long-duration growth name priced at premium multiples, but that pressure has clearly been absorbed rather than punishing the stock. The main sentiment risk is a valuation-driven crack: if the platform-monopoly framing loses intensity, the gap between story and fundamentals becomes the story, and a high-beta premium name gives back fast.
Verify before trusting this (4)
- Vet-visit and pet-spend trend data points that could crack or confirm the growth narrative
- Any target-price revisions or downgrades citing valuation vs TAM
- Shift in VIX above 20 or a risk-off rotation that would punish 1.55-beta premium names first
- Emergence of credible low-cost or digital diagnostic competitors picked up by the sell side
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 4, 2026, IDXX was $567.84. We expect it to be $505.00 by Feb 2027, and we consider it great value under $460.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 4, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.